Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 52Ovarian Neoplasms 40Multiple Myeloma 20Fallopian Tube Neoplasms 13Lymphoma 12Sarcoma 11Carcinoma, Ovarian Epithelial 11Triple Negative Breast Neoplasms 8Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Neoplasms 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 6Neoplasms, Plasma Cell 5Sarcoma, Ewing 4Prostatic Neoplasms 4Neoplasm Metastasis 4Lymphoma, Mantle-Cell 4Burkitt Lymphoma 4Rhabdomyosarcoma 3Osteosarcoma 3Lymphoma, T-Cell, Peripheral 3Leiomyosarcoma 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2

Interventions

olaparib 1liposomal doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasm Epithelial × liposomal doxorubicin × Clear all
NCT03509246 2020-01-14

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Seoul National University Hospital

Phase 2 Unknown
44 enrolled
Gynecologic

Ovarian Neoplasm Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡